Deadbolt Drug Discovery: Locking the Door to Class 1 Viral Entry by Small Molecules

Area of Science:

• Virology
• Medicinal Chemistry
• Drug Discovery

Background:

• Emerging viral pathogens necessitate novel antiviral therapeutics with enhanced efficacy.
• Viral entry inhibitors are attractive agents, blocking viruses at the earliest stage of infection.
• Many high-concern viruses, including HIV, RSV, influenza, Ebola, SARS-CoV-2, and Lassa virus, utilize Class 1 fusion proteins for entry.

Purpose of the Study:

• To review recent advances in the discovery and development of small-molecule entry inhibitors.
• To focus on inhibitors targeting viruses that encode Class 1 fusion proteins.
• To cover advancements reported within the last five years.

Main Methods:

• Literature review of scientific publications and patents.
• Analysis of small-molecule inhibitors targeting viral entry mechanisms.
• Focus on inhibitors specific to viruses employing Class 1 fusion proteins.

Main Results:

• Identification of several promising small-molecule entry inhibitors.
• Progress in targeting conserved regions of Class 1 fusion proteins.
• Diverse chemical scaffolds showing antiviral activity against various pathogens.

Conclusions:

• Small-molecule entry inhibitors represent a viable therapeutic avenue against critical viral infections.
• Continued research and development are crucial for advancing these inhibitors into clinical use.
• Targeting viral entry provides a robust strategy to combat a range of viral diseases.